Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 84 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cost Per Outcome of Nivolumab + Relatlimab Vs BRAF + MEK Inhibitor Combinations for First-Line Treatment of BRAF-mutant Advanced Melanoma
Kirollos S Hanna, Jennell Palaia, Divya Patel,Andriy Moshyk,Zheng-Yi Zhou, Fan Yang, Yiqiao Xin, Viviana Garcia-Horton
Journal of managed care & specialty pharmacypp.1-9, (2025)
Cited0Views0WOSBibtex
0
0
Predicting Overall Survival Benefit in Previously Untreated, Unresectable or Metastatic Melanoma from Improvement in Progression-Free Survival: a Correlation Meta-Analysis
Peter Mohr, Murat Kurt, Swetha Srinivasan,Andriy Moshyk, Flavia Ejzykowicz, Paul Serafini, Mir-Masoud Pourrahmat,Lisa Leung
Frontiers in Oncology (2025)
Cited0Views0Bibtex
0
0
Immune Checkpoint Inhibitors in Pediatric Patients with Melanoma: a Systematic Literature Review
Charmy Vyas,Andriy Moshyk,Gina Fusaro, Stergios Zacharoulis,Mir Sohail Fazeli, Nishu Gaind, Shirin Behyan, Pratik Thakkar
Melanoma managementno. 1 (2024): 2382075-2382075
Cited0Views0WOSBibtex
0
0
Load More
Author Statistics

#Papers: 84

#Citation: 4158

H-Index: 14

G-Index: 45

Sociability: 6

Diversity: 3

Activity: 40

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn